MDT

96.35

-1.24%↓

147.54

-0.69%↓

VEEV

235.39

-1.77%↓

HQY

86.09

-8.7%↓

PHR.US

17.1

-0.41%↓

MDT

96.35

-1.24%↓

147.54

-0.69%↓

VEEV

235.39

-1.77%↓

HQY

86.09

-8.7%↓

PHR.US

17.1

-0.41%↓

MDT

96.35

-1.24%↓

147.54

-0.69%↓

VEEV

235.39

-1.77%↓

HQY

86.09

-8.7%↓

PHR.US

17.1

-0.41%↓

MDT

96.35

-1.24%↓

147.54

-0.69%↓

VEEV

235.39

-1.77%↓

HQY

86.09

-8.7%↓

PHR.US

17.1

-0.41%↓

MDT

96.35

-1.24%↓

147.54

-0.69%↓

VEEV

235.39

-1.77%↓

HQY

86.09

-8.7%↓

PHR.US

17.1

-0.41%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

513.51 -0.05

Buy Sell

Overview

Share price change

24h

Current

Min

503.28

Max

515.06

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+14.38% upside

Dividends
By Dow Jones
Next Earnings	25 lut 2026

Market Stats
By TradingEconomics
Market Cap	4.2B 13B
Previous open	513.56
Previous close	513.51

News Sentiment

By Acuity

90%

10%

355 / 370 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 sty 2026, 00:16 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Drops Merger With JenaValve

11 sty 2026, 23:46 UTC

Market Talk

Gold Rises Amid Geopolitical Risks -- Market Talk

11 sty 2026, 23:35 UTC

Market Talk

Oil Rises Amid Middle East Tensions -- Market Talk

11 sty 2026, 23:25 UTC

Earnings

Stock Futures Drift Lower With Bank Earnings, CPI on Tap -- Barrons.com

11 sty 2026, 22:05 UTC

Market Talk

Iron Ore Outlook Weighed by Soft China Steel Markets, Rising Supply -- Market Talk

10 sty 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Copper Is the Prize in Mining Megadeals -- WSJ

10 sty 2026, 09:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

10 sty 2026, 09:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

10 sty 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 sty 2026, 22:18 UTC

Market Talk

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 sty 2026, 21:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 sty 2026, 20:39 UTC

Market Talk

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 sty 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 sty 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 sty 2026, 20:30 UTC

Market Talk

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 sty 2026, 20:15 UTC

Market Talk

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 sty 2026, 20:07 UTC

Market Talk

Global Equities Roundup: Market Talk

9 sty 2026, 20:07 UTC

Market Talk

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 sty 2026, 19:58 UTC

Acquisitions, Mergers, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 sty 2026, 19:42 UTC

Market Talk

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 sty 2026, 19:38 UTC

Acquisitions, Mergers, Takeovers

Wolters Kluwer Acquires StandardFusion >WTKWY

9 sty 2026, 19:31 UTC

Earnings

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 sty 2026, 19:28 UTC

Earnings

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 sty 2026, 18:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 sty 2026, 18:23 UTC

Market Talk

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 sty 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

14.38% upside

12 Months Forecast

Average 636.22 USD 14.38%

High 900 USD

Low 527 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

355 / 370 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.